How do you decide which tyrosine kinase inhibitor (sunitinib, pazopanib, cabozantinib) to use in the first-line setting for newly diagnosed metastatic RCC?

The choice of agents for the initial treatment of metatstatic RCCa has become more complex with the recent evidence and approvals in this disease. For newly Dx good prognosisi pts I choose either Sunitinib or Pazopanib as there is yet no evidence of something being superior. For intermediate and poo...